trending Market Intelligence /marketintelligence/en/news-insights/trending/B8MvqeoUJB29qyUklzgUZw2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

Integrated Biopharma swings to profit in fiscal Q3


ESG hits the mainstream for European private equity sponsors


What’s the Bottom Line: Credit Impact of COVID-19 on US Municipals


Banking Essentials Newsletter - February Edition, Part 2


Episode 3: Transformation of Customer Experience in 2020

Integrated Biopharma swings to profit in fiscal Q3

Integrated Biopharma said its normalized net income for the fiscal third quarter ended March 31 was $54,380, compared with a loss of $113,750 in the prior-year period.

Normalized net income excludes unusual gains or losses on a pre- and after-tax basis.

The normalized profit margin increased to 0.5% from negative 1.2% in the year-earlier period.

Total revenue climbed 13.4% on an annual basis to $11.0 million from $9.7 million, and total operating expenses increased 8.9% from the prior-year period to $10.5 million from $9.7 million.

Reported net income came to $33,000, or 0 cents per share, compared to a loss of $211,050, or a loss of 1 cents per share, in the year-earlier period.